Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies

2010 ◽  
Vol 46 (15) ◽  
pp. 2781-2787 ◽  
Author(s):  
Li-Xin Qiu ◽  
Chen Mao ◽  
Jian Zhang ◽  
Xiao-Dong Zhu ◽  
Ru-Yan Liao ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Kras Mutations ◽  
Colorectal Cancer Patients ◽  
Predictive And Prognostic Value

scholarly journals KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan: Molecular spectrum, frequency and distribution pattern

2019 ◽  
Author(s):  
Muhammad Awidi ◽  
Nidaa Ababneh ◽  
Maha Shomaf ◽  
Feras Al Fararjeh ◽  
Laila Owaidi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Distribution Pattern ◽  
Cancer Patients ◽  
Molecular Spectrum ◽  
Kras Mutations ◽  
Exon 2 ◽  
Ras Mutations ◽  
Colorectal Cancer Patients ◽  
Kras Exon

Abstract Background A constitutively active RAS protein in the absence of stimulation of the epidermal growth factor receptor (EGFR) is the result of mutations in KRAS and NRAS genes. Mutations in the KRAS exon 2 and outside exon 2 have been found to predict the resistance to anti-EGFR monoclonal therapy. A substantial proportion of metastatic colorectal cancer cases (mCRC) exhibit RAS mutations outside KRAS exon 2, particularly in KRAS exon 3 and 4 and NRAS exons 2, 3. No data about RAS mutations outside KRAS exon 2 are available for Jordanian patients with mCRC. We aim to study the molecular spectrum, frequency, and distribution pattern of KRAS and NRAS mutations in Jordanian patients with mCRC. Methods A cohort of 190 Jordanian metastatic colorectal cancer patients were enrolled in the trial. We detected mutations in exon 2 of the KRAS and NRAS gene as well as mutations outside of exon 2 using the StripAssay technique. The KRAS StripAssay covered 29 mutations and 22 NRAS mutations. Results Mutations were observed in 92 (48.42%) cases, and KRAS exon 2 accounted for 76 cases (83.69%). KRAS G12D was the most common mutation, occurring in 18 cases, followed by KRAS G12A in 16 cases, and G12T in 13 cases. Mutations outside of KRAS exon 2 represented 16.3% of the mutated cases. Among those, 6 cases (6.48%) carried mutations in NRAS exon 2, 3 and 10 cases (10.87%) in KRAS exon 3 and 4. Conclusion The frequency of NRAS and KRAS mutations outside of exon 2 appears to be higher in Jordanian patients in comparison with patients from western countries. KRAS mutations outside of exon 2 should be tested routinely to identify patients who should not be treated with anti-EGFR antibodies.

scholarly journals Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients

2020 ◽  
Vol 11 (5) ◽  
pp. 1063-1074
Author(s):  
Dong-Dong Yang ◽  
Zhan-Hong Chen ◽  
De-Shen Wang ◽  
Hong-En Yu ◽  
Jia-Huan Lu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Apolipoprotein B ◽  
Prognostic Value ◽  
Apolipoprotein A ◽  
Colorectal Cancer Patients

Prognostic value of biomarkers in metastatic colorectal cancer patients

2015 ◽  
Vol 194 (2) ◽  
pp. 343-350 ◽  
Author(s):  
Kozo Kataoka ◽  
Akiyoshi Kanazawa ◽  
Akio Nakajima ◽  
Ayane Yamaguchi ◽  
Akira Arimoto
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Colorectal Cancer Patients

scholarly journals Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis

2019 ◽  
Vol 9 (3) ◽  
pp. 1044-1057 ◽  
Author(s):  
Lauren C. Bylsma ◽  
Christina Gillezeau ◽  
Tamer A. Garawin ◽  
Michael A. Kelsh ◽  
Jon P. Fryzek ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Braf Mutations ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document